[PRESS RELEASE] – NEW YORK, June 26, 2025 – Tilray Medical, a division of Tilray Brands Inc. and a global leader in medical cannabis, empowering the therapeutic alliance between patients and health care practitioners to make informed individualized health decisions, announced the publication of a scientific study. This new research focuses on comparing the bioavailability of different cannabinoid formulations, taking a step forward in the understanding of medical cannabis.

The study aimed to assess the pharmacokinetic parameters and relative bioavailability of two D9-tetrahydrocannabinol: cannabidiol (THC:CBD) formulations:

1. an orally administered: Tilray THC:CBD extract; and
2. an oromucosally administered nabiximols formulation.

This pilot crossover study counterbalanced:

• 1 mL of orally administered Tilray THC:CBD extract (10 mg/mL each of THC and CBD); and
• oromucosally administered nabiximols (four sprays of 2.7 mg THC and 2.5 mg CBD per spray, for a total dose of 10.8 mg THC and 10 mg CBD).

Blood samples were obtained pre-dose and at 16 post-dose time points over 24 hours. Pharmacokinetic parameters were calculated for THC, 11-hydroxy-tetrahydrocannabinol (11-OH-THC), and CBD.

Conducted with 12 healthy volunteers (six male, six female) under fasting conditions, the results revealed that the Cmax for THC and CBD was significantly higher for the Tilray THC:CBD extract compared to nabiximols, and neither Tmax nor AUC was significantly different for the two treatments. Interestingly, the Cmax for nabiximols was significantly higher in males compared to females. Under both treatment conditions, THC and CBD were undetectable 24 hours post-dose, and 11-OH-THC was markedly reduced from its peak. Notably, no serious adverse events were reported.

This pilot study shows that oral administration of Tilray THC:CBD extract formulation achieved higher THC and CBD concentrations within a shorter timeframe compared to the oromucosal delivery of nabiximols. These findings may have significant implications for clinical populations using these formulations therapeutically.

José Tempero, Tilray’s medical director, said, “By advancing our understanding of cannabinoid pharmacokinetics, we are better equipped to develop formulations that can significantly enhance therapeutic outcomes. We extend our heartfelt thanks to our partners in this study for their invaluable contributions and collaboration.”

Denise Faltishchek, chief strategy officer and head of International at Tilray, said, “This pioneering research exemplifies our commitment to advancing the science of medical cannabis. By deepening our understanding of cannabinoid pharmacokinetics, we strive to enhance the therapeutic potential of our products, ultimately improving the quality of life for patients globally. Our goal is to continue driving innovation and providing patients with safe, effective, consistent and reliable medical cannabis solutions for patients around the world.”

Tilray Medical is a leading provider of EU-GMP-certified and pharmaceutical-grade medical cannabis products, having supplied more than 20 countries with a comprehensive portfolio of THC and CBD products. Tilray has supported medical trials globally, across Europe, Canada, the United States, Australia, and Latin America, studying the efficacy of medical cannabis as a treatment for indications including pediatric epilepsy, refractory pediatric epilepsy, cancer-induced nausea and vomiting, HIV, essential tremor, breast cancer disorders, post-traumatic stress disorder and alcohol-use disorders.

[PRESS RELEASE] – EDMONTON, Alberta, June 26, 2025 – Aurora Cannabis Inc., the Canadian-based leading global medical cannabis company, is pleased to have recently expanded the eligibility of its medical compassionate pricing program in Canada.

As part of the company’s ongoing commitment to making medical cannabis more accessible to patients, the yearly income eligibility of the program has increased from CA$40,000 to CA$60,000 for Aurora patients through AuroraMedical.com.

“As over half of the country’s adult population fits within this income threshold, our compassionate pricing program represents the most accessible, inclusive pricing plan to access medical cannabis in Canada,” said Geoff Hoover, senior vice president of Canadian Commercial at Aurora. “We’re committed to breaking down barriers to access high-quality medical cannabis, and this change empowers more patients to explore different treatment options at pricing they can afford.”

The changes to the compassionate pricing program are available alongside new medical cannabis products, including:

• Aurora | Mediora Minis – Cannatonic CBD Flower, Sativa (10mg)
• Daily Special | Sativa J’s – THC Pre-Rolls, Sativa (7 x 0.3g)
• WMMC | Seasonal Stash Petro Biscuit – THC Flower, Indica (10mg)

In addition to the compassionate pricing program, Aurora offers resources to seniors, pediatric patients, veterans, first responders, and others seeking care through medical cannabis. Patients can visit www.auroramedical.com for more information and to connect with the Aurora client care team for further support.